Brief: Atreca And Xencor To Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target
06/02/2023 16:55
Feb 6 (Reuters) - Atreca Inc BCEL.O :
* ATRECA AND XENCOR TO DEVELOP T CELL ENGAGING BISPECIFIC
ANTIBODY
DIRECTED AGAINST NOVEL SOLID TUMOR TARGET
Source text for Eikon: ID:nGNX61QKHQ
Further company coverage: BCEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atreca
See all newsBrief: Baker Bros Advisors Reports 19.99% Passive Stake In Atreca As Of Dec 31, 2023 - SEC Filing
Brief: Immunome To Acquire Antibody-Related Assets And Materials From Atreca
Brief: Atreca Says On Dec 19 Asset Sale And Other Transactions Contemplated By Agreement, Board Approved Liquidation And Dissolution Of Co
Brief: Atreca Q3 basic EPS USD -0.92
Brief: Atreca Announces Agreement To Terminate Lease And Departure Of CFO Herb Cross